Evaluation of the BD Phoenix100 System and Colistin Broth Disk Elution Method for Antimicrobial Susceptibility Testing of Colistin Against Gram-negative Bacteria

2019 ◽  
Vol 53 (3) ◽  
pp. 254-261 ◽  
Author(s):  
Özlem KOYUNCU ÖZYURT ◽  
Betil ÖZHAK ◽  
Dilara ÖĞÜNÇ ◽  
Emre YILDIZ ◽  
Dilek ÇOLAK ◽  
...  
2014 ◽  
Vol 28 (3) ◽  
Author(s):  
Andrea Zappavigna ◽  
Enrica Cavatorta ◽  
Rossana Chiarabini ◽  
Roberta Schiavo ◽  
Daniela Padrini ◽  
...  

2013 ◽  
Vol 57 (4) ◽  
pp. 1989-1991 ◽  
Author(s):  
Bryan Coburn ◽  
Baldwin Toye ◽  
Prasad Rawte ◽  
Frances B. Jamieson ◽  
David J. Farrell ◽  
...  

ABSTRACTThe “HACEK” organisms are a group of fastidious Gram-negative bacteria that cause a variety of infections, including infective endocarditis. Antimicrobial susceptibility testing is not universally available, and therapy for these infections is often empirical. We report the antimicrobial susceptibilities of 70 clinical HACEK isolates to 18 antimicrobials. All isolates were susceptible to ceftriaxone and levofloxacin, indicating that these agents remain appropriate empirical choices for the treatment of infections with this group of organisms.


Author(s):  
Måns Ullberg ◽  
Volkan Özenci

Abstract Rapid identification and antimicrobial susceptibility testing remain a crucial step for early efficient therapy of bloodstream infections. Traditional methods require turnaround times of at least 2 days, while rapid procedures are often associated with extended hands-on time. The Accelerate Pheno™ System provides microbial identification results within 90 min and susceptibility data in approximately 7 h directly from positive blood cultures with only few minutes of hands-on time. The aim of this study was, therefore, to evaluate the performance of the Accelerate Pheno™ System in identification and antimicrobial susceptibility testing of both Gram-positive and Gram-negative bacteria directly from clinical blood culture samples. We analyzed 108 and 67 blood culture bottles using the Accelerate PhenoTest™ BC kit with software version v1.0 and the FDA-cleared version v1.2, respectively. Reliable identification was achieved for Enterobacteriaceae, staphylococci, and enterococci, with 76/80 (95%), 42/46 (91%), and 10/11 (91%) correct identifications. Limitations were observed in the identification of streptococci, including Streptococcus pneumoniae and Streptococcus pyogenes, and coagulase-negative staphylococci. Antimicrobial susceptibility results for Enterobacteriaceae, for amikacin, ertapenem, ciprofloxacin, gentamicin, meropenem, and piperacillin-tazobactam ranged between 86 and 100% categorical agreement. Using v1.2, results for ceftazidime showed 100% concordance with the reference method. For staphylococci, the overall performance reached 92% using v1.2. Qualitative tests for detection of methicillin or macrolide-lincosamide-streptogramin B (MLSB) resistance caused major and very major errors for isolates. Overall, the present data show that the Accelerate Pheno™ system can, in combination with Gram stain, be used as a rapid complementation to standard microbial diagnosis of bloodstream infections.


Sign in / Sign up

Export Citation Format

Share Document